within Pharmacolibrary.Drugs.ATC.C;

model C01BA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 0.11833333333333333,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008666666666666666,
    Tlag           = 1200
  );

  annotation(Documentation(
    info ="<html><body><p>Quinidine is a class Ia antiarrhythmic agent historically used to treat certain types of cardiac arrhythmias, such as atrial fibrillation and ventricular arrhythmias. It acts by blocking sodium channels and increasing the action potential duration. While quinidine is less commonly used today due to side effects and the availability of safer agents, it remains approved in some regions for specific arrhythmic indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following oral administration.</p><h4>References</h4><ol><li><p>Bhardwaj, R, et al., &amp; Bertz, R (2022). P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. <i>Clinical pharmacology in drug development</i> 11(7) 889–897. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1088&quot;>10.1002/cpdd.1088</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35304977/&quot;>https://pubmed.ncbi.nlm.nih.gov/35304977</a></p></li><li><p>Fattinger, K, et al., &amp; Follath, F (1991). Population pharmacokinetics of quinidine. <i>British journal of clinical pharmacology</i> 31(3) 279–286. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1991.tb05531.x&quot;>10.1111/j.1365-2125.1991.tb05531.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2054269/&quot;>https://pubmed.ncbi.nlm.nih.gov/2054269</a></p></li><li><p>Maeda, K, et al., &amp; Sugiyama, Y (2011). Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. <i>Clinical pharmacology and therapeutics</i> 90(2) 263–270. DOI:<a href=&quot;https://doi.org/10.1038/clpt.2011.108&quot;>10.1038/clpt.2011.108</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21716273/&quot;>https://pubmed.ncbi.nlm.nih.gov/21716273</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01BA01;
